Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18223676rdf:typepubmed:Citationlld:pubmed
pubmed-article:18223676lifeskim:mentionsumls-concept:C0005955lld:lifeskim
pubmed-article:18223676lifeskim:mentionsumls-concept:C1513792lld:lifeskim
pubmed-article:18223676lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:18223676lifeskim:mentionsumls-concept:C1334501lld:lifeskim
pubmed-article:18223676lifeskim:mentionsumls-concept:C1428869lld:lifeskim
pubmed-article:18223676lifeskim:mentionsumls-concept:C0000894lld:lifeskim
pubmed-article:18223676lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:18223676lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:18223676lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:18223676pubmed:issue27lld:pubmed
pubmed-article:18223676pubmed:dateCreated2008-6-19lld:pubmed
pubmed-article:18223676pubmed:abstractTextIdentifying genetic pathways that cooperate in leukemogenesis facilitates our understanding of the molecular mechanisms at play. Interferon consensus sequence-binding protein (ICSBP) is a tumor suppressor, whose downregulation cooperates with BCR-ABL and NUP98-TOP1 gene products to accelerate leukemia induction in mouse models. Similarly, Meis1 synergizes with HoxA9 or NUP98-HOX (but not NUP98-TOP1) fusion genes to promote the early onset of leukemia. To investigate whether Icsbp deficiency interacts with Meis1 or its family member Meis3, we transplanted Icsbp(-/-) bone marrow (BM) cells after transduction with Meis1 or Meis3 retroviral vectors. Here, we show that enforced expression of Meis1 or Meis3 in Icsbp(-/-) BM cells induces a fatal, invasive myeloproliferative disease. Secondary mutations, such as activation of Mn1, led to the progression to acute myeloid leukemia in a few mice. Interestingly, expression of endogenous Meis1 and Meis3 mRNAs was repressed in the granulocytic progenitor population of Icsbp(-/-) mice. These results reveal a novel collaboration between Icsbp deficiency and Meis1/Meis3 in the acceleration of chronic myeloid leukemia-like disease.lld:pubmed
pubmed-article:18223676pubmed:languageenglld:pubmed
pubmed-article:18223676pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18223676pubmed:citationSubsetIMlld:pubmed
pubmed-article:18223676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18223676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18223676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18223676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18223676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18223676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18223676pubmed:statusMEDLINElld:pubmed
pubmed-article:18223676pubmed:monthJunlld:pubmed
pubmed-article:18223676pubmed:issn1476-5594lld:pubmed
pubmed-article:18223676pubmed:authorpubmed-author:ZieglerMMlld:pubmed
pubmed-article:18223676pubmed:authorpubmed-author:HaraTTlld:pubmed
pubmed-article:18223676pubmed:authorpubmed-author:OkamotoSSlld:pubmed
pubmed-article:18223676pubmed:authorpubmed-author:LöhlerJJlld:pubmed
pubmed-article:18223676pubmed:authorpubmed-author:KazamaRRlld:pubmed
pubmed-article:18223676pubmed:authorpubmed-author:StockingCClld:pubmed
pubmed-article:18223676pubmed:authorpubmed-author:SchwiegerMMlld:pubmed
pubmed-article:18223676pubmed:authorpubmed-author:MinehataKKlld:pubmed
pubmed-article:18223676pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18223676pubmed:day19lld:pubmed
pubmed-article:18223676pubmed:volume27lld:pubmed
pubmed-article:18223676pubmed:ownerNLMlld:pubmed
pubmed-article:18223676pubmed:authorsCompleteYlld:pubmed
pubmed-article:18223676pubmed:pagination3865-9lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:meshHeadingpubmed-meshheading:18223676...lld:pubmed
pubmed-article:18223676pubmed:year2008lld:pubmed
pubmed-article:18223676pubmed:articleTitleAcceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells.lld:pubmed
pubmed-article:18223676pubmed:affiliationStem Cell Project Group, The Tokyo Metropolitan Institute of Medical Science, Tokyo Metropolitan Organization for Medical Research, Tokyo, Japan. thara@rinshoken.or.jplld:pubmed
pubmed-article:18223676pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18223676pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:15900entrezgene:pubmedpubmed-article:18223676lld:entrezgene
entrez-gene:17268entrezgene:pubmedpubmed-article:18223676lld:entrezgene
entrez-gene:17537entrezgene:pubmedpubmed-article:18223676lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18223676lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18223676lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18223676lld:entrezgene